NCT04012775 - Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

September 24, 2018

Study Completion Date

September 24, 2018

Conditions

Diabetes Mellitus, Type 2

Interventions

BIOLOGICAL

Insulin Humulin® NPH

4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses

BIOLOGICAL

Insulin Rinsulin® NPH

4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses

Trial Locations (14)

Moscow Endocrinological Dispensary, Moscow

Moscow Clinical Hospital № 71, Moscow

Clinical Hospital № 3, Yaroslavl

V.A. Baranov Republic Hospital, Petrozavodsk

City Polyclinic № 6, Saint Petersburg

City Hospital № 2, Saint Petersburg

City Polyclinic № 17, Saint Petersburg

Medical Sanitary Unit № 157, Saint Petersburg

Institute of Medical Research, Saint Petersburg

Research Center Eco-Safety, Saint Petersburg

Saint Petersburg State Diagnostic Center № 85, Saint Petersburg

Diabetes Center, Samara

Chelyabinsk Railway Clinical Hospital, Chelyabinsk

Nizhny Novgorod Regional Clinical Hospital, Nizhny Novgorod